The argenx Immunology Innovation Program

A co-creation engine built to speed scientific discovery

Teaming Up from Discovery to Development and Beyond

The Immunology Innovation Program (IIP) is where disease biology experts team up with antibody engineers from argenx to advance groundbreaking science and accelerate potential new therapies for patients.

Discover

Collaborators bring deep mechanistic understanding of disease biology, targets, and pathways

Design

SIMPLE Antibody™ platform enables argenx to generate antibodies that recognize disease targets

Co-Create

Proprietary technologies allow argenx to optimize and engineer antibodies for first-in-human

Advance

Together, these collaborations push optimized antibodies into clinical development

Combining argenx antibody engineering technologies with the disease biology expertise of our partners, collaborations typically yield a preclinical lead antibody candidate in roughly one year.


Immunization	Antibody Candidate	Preclinical Lead
8 Weeks*	3 Months	1 Year

*Represents use of SIMPLE Antibody™ platform to produce diverse panels of antibodies with a high human homology in their V-regions.

Our Antibody Technologies are Transforming Therapeutic Discovery and Development

V-Region Capabilities Unlock Novel and Complex Targets

SIMPLE Antibody™ Platform



Fc-Engineering Capabilities for Therapeutic Precision

- Half-life extension
- Enhanced cell killing
- Clear autoantibodies
- Clear target proteins
- Bispecific antibodies

> **"The relationship with argenx feels like a true partnership because you're sharing information, you're both benefiting, you're both communicating. It's been a lot of fun for us."**
>
> **Dr. Steve Burden**
> Senior Lecturer at Harvard University and ARGX-119 Collaborator

Interested in learning more or partnering with us?

The Proof is in the Partnerships

20+ | Partner institutions

9 | First-in-class targets identified by IIP

8 | Molecules that have entered clinical development

4 | New candidates emerged in 2025

3 | Additional molecules expected to enter Phase 1 research in 2026

35+ | Indications with potential applicability being researched

> **"Through our collaboration with argenx, we had access to their key technologies. They created a whole class of antibodies for us to work with. The speed by which this was achieved surprised all of us."**
>
> **Dr. Bart Lambrecht**
> VIB, Flemish Institute for Biotechnology

Therapeutic Areas of Interest

Our platforms make it possible to collaborate in these areas, or any others where the disease has an antibody-amenable target:



Neurology | **Neuromuscular disease** | **Immunology** | **Rheumatology** | **Nephrology** | **Hematology** | **Fibrosis** | **Dermatology**

At argenx, we work to transform cutting-edge science into life-changing outcomes for patients. We believe that people with autoimmune conditions and other serious diseases should not have a life held back by their diagnosis.

We're pushing the boundaries of what's possible in antibody engineering. As of today, our science is helping improve the health of ~19,000 people around the world living with Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Immune Thrombocytopenia. Our goal is to reach 50,000 patients by 2030 with 10 approved indications and 5 molecules in late-stage trials.

Interested in learning more or partnering with us?

www.argenx.com

© 2026 argenx. All rights reserved. MED-US-NON-2400034 v4.0 06/2026